March 4, 2026 – RSVP and join us on April 15, 2026 for the 13th annual Falcons’ Fortunes pitch competition and networking event. Watch six Ontario entrepreneurs pitch their breakthrough cancer innovation and compete for the $100,000 award.
Category: Portfolio
Hamilton, Ontario startup NodeAI wins Falcons’ Fortunes 2025 for revolutionary lung cancer diagnostics using artificial intelligence
March 25, 2025 – The winning pitch at FACIT’s sold-out annual Falcons’ Fortunes pitch competition and recipient of the $100,000 Ernsting Entrepreneurship award was delivered by Dr. Waël Hanna, co-founder and Chief Medical Officer of NodeAI Diagnostics (“NodeAI”). The Hamilton, Ontario based start-up is leveraging the power of artificial intelligence to improve the speed and accuracy in evaluating and staging non-small cell lung cancer (NSCLC) patients. The innovation is poised to address a long standing gap in lung cancer diagnostics that can better inform treatment decisions and ultimately improved patient outcomes.
Idea to Investment Podcast: How FACIT’s support propels early cancer innovations
January 17, 2025 – FACIT’s David Koehler, Director of Fund Operations, appeared on TechAlliance’s Idea to Investment podcast along with Saumik Biswas, President, CEO and Founder of Tenomix Inc. based in London, Ontario. Tenomix’s advancements exemplifies how FACIT’s continuum of commercialization programs can strategically capitalize on homegrown talent and innovations to spur promising start-ups to grow roots in Ontario and bring cancer solutions to benefit patients sooner.
Esphera SynBio closes seed financing round to advance their lead designer cancer vaccine
Pitch Your Cancer Innovation at Falcons’ Fortunes 2025
FACIT investment in cTRL Therapeutics focuses cell therapy R&D on Ontario for patients with cancer
October 10, 2024 – cTRL Therapeutics announced it is strengthening its research and development operations in Canada. Following an investment by FACIT, the company will establish a state-of-the-art laboratory and leverage Ontario’s world-leading cancer research network to accelerate advancement of its cancer therapeutics pipeline to benefit patients sooner.
Radiant Biotherapeutics reaches milestone to advance its new class of therapeutics against complex cancers
September 11, 2024 – FACIT seeded start-up, Radiant Biotherapeutics (“Radiant”), announced the closing of Series A financing to advance the company’s proprietary multi-specific therapeutics for patients with complex cancers. Radiant’s unique multi-valent antibody platform, called Multabody™, generates best-in-class antibodies with superior potency against multiple target sites implicated in heterogenous diseases such as cancers and can potentially improve patient outcome.
FACIT portfolio company HDAX Therapeutics closes seed financing to target CNS cancers and neuropathies
September 5, 2024 – FACIT congratulates HDAX Therapeutics (“HDAX”) on the closing of a seed financing round to develop their best-in-class HDAC therapeutics for the treatment of a serious cancer conditions. Capital from the investor group, which included an investment from FACIT’s Compass Rose Oncology Fund, will empower HDAX to address the debilitating neuropathic pain frequently experienced by patients with cancer.
FACIT-seeded Fusion Pharmaceuticals acquired for up to US$2.4B by AstraZeneca
March 20, 2024 – FACIT’s portfolio company Fusion Pharmaceuticals is being acquired by AstraZeneca for a total transaction value of up to $2.4 billion. Congratulations to the team at Fusion for building value over the last decade that will have a lasting impact on patients with cancer and the Ontario economy.